Baoyuan Biomedical
Hangzhou
About Baoyuan Biomedical
Baoyuan Biomedical is a clinical stage company focused on acquiring, developing and commercializing innovative drugs that improve human health and quality of life, and is committed to innovative drug development that does not meet clinical needs. Its main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Total funding: $14.5M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2019)
Industries & Categories
Health Care, Medical, Medical Device
Canonical: https://fsome.com/organization/baoyuan-biomedical-50604 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.